A Retrospective Analysis of 1,231 Patients with Anemia After Surgical Treatment of Hyperthyroidism

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2018 Dec 14

PMID 30542418

Authors

Ruisha Tu

Hongfeng Shen

Qicong Zhu

Gaocai Mao

Xiaojiang Xu

Shuyong Yu

Affiliations

Soon will be listed here.

Abstract

This study retrospectively analyzed the clinical and pathological data of 1,231 patients affected by anemia after surgical treatment of hyperthyroidism to explore the influencing factors of anemia after surgical treatment of hyperthyroidism. The clinical data of 1,231 patients affected by anemia after surgical treatment of hyperthyroidism from 1987 to 2017 were analyzed. Clinical data included the surgery methods, sex, age and pathological types. SPSS 22.0 statistical software was used for all statistical analyses. Correlation analyses were performed by using logistic regression analysis, and other enumeration data were subjected to χ test. p<0.05 was considered to be statistically significant. The occurrence of anemia after surgical treatment of hyperthyroidism was significantly correlated with age and pathological types (p<0.05). Correlation analysis also showed that age and pathological types were significantly correlated with the occurrence of anemia after surgical treatment of hyperthyroidism. Age and pathological types may be the risk factors for anemia in patients with surgical treatment of hyperthyroidism. Age and pathological type were significantly correlated with the occurrence of anemia after surgical treatment of hyperthyroidism, and may be risk factors for this disease.

References

Rivkees S . Controversies in the management of Graves' disease in children. J Endocrinol Invest. 2016; 39(11):1247-1257. DOI: 10.1007/s40618-016-0477-x. View

Song X, Meng Z, Jia Q, Zhang L, Xu K, Tan J . Different Radioiodine Dose for Remnant Thyroid Ablation in Patients With Differentiated Thyroid Cancer: A Meta-analysis. Clin Nucl Med. 2015; 40(10):774-9. DOI: 10.1097/RLU.0000000000000914. View

Ross D, Burch H, Cooper D, Greenlee M, Laurberg P, Maia A . 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016; 26(10):1343-1421. DOI: 10.1089/thy.2016.0229. View

Dong L, Sun X, Xiang C, Wu J, Yu P . Hashimoto's thyroiditis and papillary carcinoma in an adolescent girl: A case report. Mol Clin Oncol. 2016; 5(1):129-131. PMC: 4906656. DOI: 10.3892/mco.2016.895. View

Yu X, Wang Y, Wang P, Ji C, Miao C, Zheng S . Primary thyroid paraganglioma mimicking medullary thyroid carcinoma: A case report. Oncol Lett. 2015; 10(2):1000-1002. PMC: 4509088. DOI: 10.3892/ol.2015.3292. View

Evenson A, Mitchell J, Wei W, Poylin V, Parangi S, Hasselgren P . The gene expression and activity of calpains and the muscle wasting-associated ubiquitin ligases, atrogin-1 and MuRF1, are not altered in patients with primary hyperparathyroidism. Int J Mol Med. 2006; 18(3):471-5. View

MRabet-Bensalah K, Aubert C, Coslovsky M, Collet T, Baumgartner C, den Elzen W . Thyroid dysfunction and anaemia in a large population-based study. Clin Endocrinol (Oxf). 2015; 84(4):627-31. DOI: 10.1111/cen.12994. View

Wang L, Wang T, Sun Q, Qie Y . Correlation between thyroglobulin gene polymorphisms and autoimmune thyroid disease. Mol Med Rep. 2015; 12(3):4469-4475. DOI: 10.3892/mmr.2015.3978. View

Jiang Y, Hu K, Xie W, Zheng G, Sun J, Zheng Y . Hyperthyroidism with concurrent FMS-like tyrosine kinase 3-internal tandem duplication-positive acute promyelocytic leukemia: A case report and review of the literature. Oncol Lett. 2014; 7(2):419-422. PMC: 3881699. DOI: 10.3892/ol.2013.1721. View

10.

Roomi M, Kalinovsky T, Rath M, Niedzwiecki A . Cytokines, inducers and inhibitors modulate MMP-2 and MMP‑9 secretion by human Fanconi anemia immortalized fibroblasts. Oncol Rep. 2017; 37(3):1842-1848. DOI: 10.3892/or.2017.5368. View

11.

Ma C, Xie J, Wang H, Li J, Chen S . Radioiodine therapy versus antithyroid medications for Graves' disease. Cochrane Database Syst Rev. 2016; 2:CD010094. PMC: 10517434. DOI: 10.1002/14651858.CD010094.pub2. View

12.

Fischli S, von Wyl V, Trummler M, Konrad D, Wueest S, Ruefer A . Iron metabolism in patients with Graves' hyperthyroidism. Clin Endocrinol (Oxf). 2017; 87(5):609-616. DOI: 10.1111/cen.13450. View

13.

Zhou S, Zhuang Y, Zhao W, Jiang B, Pan H, Zhang X . Protective roles of erythropoiesis-stimulating proteins in chronic heart failure with anemia. Exp Ther Med. 2014; 8(3):863-870. PMC: 4113650. DOI: 10.3892/etm.2014.1845. View

14.

Yang L, Shen X, Yan S, Yuan X, Lu J, Wei W . HbA1c in the diagnosis of diabetes and abnormal glucose tolerance in patients with Graves' hyperthyroidism. Diabetes Res Clin Pract. 2013; 101(1):28-34. DOI: 10.1016/j.diabres.2013.04.008. View

15.

Zhang W, Gao R, Yu Y, Guo K, Hou P, Yu M . Iodine-131 induces apoptosis in HTori-3 human thyrocyte cell line and G2/M phase arrest in a p53-independent pathway. Mol Med Rep. 2014; 11(4):3148-54. DOI: 10.3892/mmr.2014.3096. View

16.

Rosario P, Batista K, Calsolari M . Radioiodine-induced oxidative stress in patients with differentiated thyroid carcinoma and effect of supplementation with vitamins C and E and selenium (antioxidants). Arch Endocrinol Metab. 2016; 60(4):328-32. PMC: 10118725. DOI: 10.1590/2359-3997000000128. View

17.

Krohn T, Hanscheid H, Muller B, Behrendt F, Heinzel A, Mottaghy F . Maximum dose rate is a determinant of hypothyroidism after 131I therapy of Graves' disease but the total thyroid absorbed dose is not. J Clin Endocrinol Metab. 2014; 99(11):4109-15. DOI: 10.1210/jc.2014-1347. View

18.

Li H, Yuan Y, Zhang Y, He Q, Xu R, Ge F . Celastrol inhibits IL-1β-induced inflammation in orbital fibroblasts through the suppression of NF-κB activity. Mol Med Rep. 2016; 14(3):2799-806. DOI: 10.3892/mmr.2016.5570. View

19.

Liu L, Lu H, Liu Y, Liu C, Xun C . Predicting relapse of Graves' disease following treatment with antithyroid drugs. Exp Ther Med. 2016; 11(4):1453-1458. PMC: 4812122. DOI: 10.3892/etm.2016.3058. View

20.

Reddy P, Harinarayan C, Sachan A, Suresh V, Rajagopal G . Bone disease in thyrotoxicosis. Indian J Med Res. 2012; 135:277-86. PMC: 3361862. View